Cancer Drugs
Search documents
Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026
Yahoo Finance· 2026-01-16 19:17
Johnson & Johnson (NYSE:JNJ) is among the most profitable US stocks to buy. On January 9, Lee Hambright at Bernstein raised the price target on Johnson & Johnson (NYSE:JNJ) to $208 from $193 and kept the ‘Market Perform’ rating unchanged, according to TheFly. The firm noted that U.S. healthcare stocks have shown improved performance over the last few months, following a low point in September 2025. With clearer visibility into macroeconomic uncertainties that have challenged healthcare stocks throughout 2 ...
